According to a new research report by RNCOS entitled, "US Generic Drug Market Outlook 2018", The large number of drugs going off-patent in the US presents opportunities for domestic as well as foreign generic drug makers to introduce Generic equivalents of branded products. Some of the players competing in the market include Sun Pharmaceutical Industries Ltd, Teva, Mylan, Actavis, Lupin, Dr Reddy's Laboratories Ltd, Cipla Ltd, Novartis, Roche and Daiichi Sankyo. Patent expirations are estimated to affect more than US$ 30 Billion sales of branded drugs in 2014. A generic drug generally takes about 80% of the branded drug market share and prices at about 20% of the branded counterpart. Anticipating the opportunity, drug makers around the globe are building a strong pipeline of products to be sold in the US and have been filing abbreviated new drug applications (ANDA) to the US Food and Drug Administration (FDA), seeking approval for generic drugs. Some of the major drugs whose patents are on the verge of expiry include Teva Pharmaceutical industries Ltd's multiple sclerosis brand Capaxone, AstraZeneca SA's hyperacidity drug Nexium, and Boehringer Ingelheim's cardiac drug Micardis.